News articles

News article list

• NICE approves life-changing gene therapy for treating spinal muscular atrophy

  A new one-off gene therapy for babies with the rare genetic disorder spinal muscular atrophy (SMA) is set to become the most expensive treatment ever approved by NICE.

• NICE announces start of review of nusinersen Managed Access Agreement

  NICE has today (29 October 2020) announced that it has begun the process to review data collected as part of the Managed Access Agreement (MAA) for nusinersen.

• NICE recommends ‘game changing’ histology independent cancer drug

  Larotrectinib (also called Vitrakvi and made by Bayer), is a new treatment for a range of cancers, has been recommended for use in the Cancer Drugs Fund (CDF).

• Additional evidence needed to assess histology-independent cancer drugs

  A paper published and co-authored by NICE staff looks at how histology-independent cancer drugs might be appraised.